HAG
IBIO icon

HighPoint Advisor Group’s iBio IBIO Stock Holding History

HighPoint Advisor Group’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$7K Buy
+52
New +$7.82K ﹤0.01% 528
2021
Q3 		$28K Hold
52
– – ﹤0.01% 547
2021
Q2 		$39K Hold
52
– – ﹤0.01% 534
2021
Q1 		$38K Sell
52
-43
-45% -$37.5K ﹤0.01% 494
2020
Q4 		$125K Buy
+95
New +$77.4K 0.02% 452

Other funds holding IBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HighPoint Advisor Group's IBIO Position: Q2 2022 in Review

HighPoint Advisor Group opened a new position in iBio (IBIO) in Q2 2022: 52 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #528 among its holdings. This is a return to the name: HighPoint Advisor Group previously reported a position in IBIO as recently as Q3 2021.

HighPoint Advisor Group first reported a position in IBIO in Q4 2020 and has held it in 5 quarters since. The position peaked at $125K in Q4 2020. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

  • HighPoint Advisor Group held 52 shares of iBio worth $7K as of Q2 2022.
  • iBio was a new HighPoint Advisor Group position in Q2 2022.
  • iBio made up ﹤0.01% of HighPoint Advisor Group's portfolio in Q2 2022, its #528 holding.
  • HighPoint Advisor Group first reported a position in iBio in Q4 2020 and has held it in 5 quarters since.
  • HighPoint Advisor Group's iBio position peaked at $125K in Q4 2020.
  • 53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on HighPoint Advisor Group's 13F filing for Q2 2022, filed 15 Aug 2022.